Bellevue Life Sciences Acquisition Corp. Files Q2 2024 10-Q

TL;DR

Bellevue Life Sciences Acquisition Corp. filed its Q2 10-Q. All systems go.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, operates in the Surgical & Medical Instruments & Apparatus sector. Its principal executive offices are located in Bellevue, Washington.

Why It Matters

This filing provides an update on the financial health and operational status of Bellevue Life Sciences Acquisition Corp. for the second quarter of 2024.

Risk Assessment

Risk Level: low — This filing is a routine quarterly report and does not contain significant new risks or material adverse events.

Key Numbers

• 20240630 — Period End Date (The report covers the fiscal period ending on this date.)
• 20240819 — Filing Date (The date the 10-Q was officially filed with the SEC.)

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 10-Q
• 0001840425 (company) — Central Index Key for Bellevue Life Sciences Acquisition Corp.
• DE (company) — State of incorporation
• WA (company) — State of business address
• 10900 NE 4TH STREET, SUITE 2300 (company) — Business address
• BELLEVUE (company) — City of business address
• 98004 (company) — ZIP code of business address
• 425-635-7700 (company) — Business phone number

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $10.175 — st Account (initially anticipated to be $10.175 per Public Share plus any pro rata inte

Filing Documents

• d826227d10q.htm (10-Q) — 670KB
• d826227dex311.htm (EX-31.1) — 11KB
• d826227dex312.htm (EX-31.2) — 11KB
• d826227dex321.htm (EX-32.1) — 6KB
• d826227dex322.htm (EX-32.2) — 5KB
• 0001193125-24-202828.txt ( ) — 3714KB
• blacu-20240630.xsd (EX-101.SCH) — 38KB
• blacu-20240630_cal.xml (EX-101.CAL) — 22KB
• blacu-20240630_def.xml (EX-101.DEF) — 182KB
• blacu-20240630_lab.xml (EX-101.LAB) — 225KB
• blacu-20240630_pre.xml (EX-101.PRE) — 220KB
• d826227d10q_htm.xml (XML) — 392KB

Financial Statements

Financial Statements 1 Condensed Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Condensed Statements of Operations (unaudited) for the three and six months ended June 30, 2024 and 2023 2 Condensed Statements of Changes in Stockholders' Deficit (unaudited) for the three and six months ended June 30, 2024 and 2023 3 Condensed Statements of Cash Flows (unaudited) for the six months ended June 30, 2024 and 2023 4 Notes to Condensed Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II Other Information 32 Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item1.

Financial Statements

Financial Statements BELLEVUE LIFE SCIENCES ACQUISITION CORP. CONDENSED BALANCE SHEETS June 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash $ 119,116 $ 15,419 Prepaid expenses 47,712 7,208 Total current assets 166,828 22,627 Investments held in Trust Account 20,466,815 36,605,106 Total Assets $ 20,633,643 $ 36,627,733 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable and accrued expenses $ 1,052,379 $ 1,081,753 Income taxes payable 240,334 524,562 Excise tax payable 530,415 359,957 Notes payable - related party 1,498,000 — Due to affiliate 97,000 72,000 Total current liabilities 3,418,128 2,038,272 Deferred underwriting commissions 2,070,000 2,070,000 Total liabilities 5,488,128 4,108,272 Commitments and Contingencies Common stock subject to possible redemption, 1,886,221 shares issued and outstanding at redemption value of $ 10.62 per share and 3,467,954 shares issued and outstanding at redemption value of $ 10.50 per share at June 30, 2024 and December 31, 2023, respectively 20,049,090 36,426,253 Stockholders' Deficit Preferred stock, $ 0.0001 par value; 1,000,000 shares authorized; no ne issued or outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 2,155,000 issued and outstanding (excluding 1,886,221 shares subject to possible redemption) at June 30, 2024 and 2,155,000 issued and outstanding (excluding 3,467,954 shares subject to possible redemption) at December 31, 2023 216 216 Additional paid-in capital — — Accumulated deficit ( 4,903,791 ) ( 3,907,008 ) Total stockholders' deficit ( 4,903,575 ) ( 3,906,792 ) Total Liabilities and Stockholders' Deficit $ 20,633,643 $ 36,627,733 The accompanying notes are an integral part of the unaudited condensed financial statements. 1 Table of Contents BELLEVUE LIFE SCIENCES ACQU

View Full Filing

View this 10-Q filing on SEC EDGAR